Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
SPONSORED CONTENTUncompromising renal + sensitivities care.Managing pain from canine OA doesn’t have to be complicated. Discover an approach that doesn’t just treat pain, but addresses inflammation, too. + Learn More
